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Abstract
Purpose of review Cardiovascular magnetic resonance (CMR) is frequently used in the
investigation of suspected cardiac disease in athletes. In this review, we discuss how
CMR can be used in athletes with suspected cardiomyopathy with particular reference
to volumetric analysis and tissue characterization. We also discuss the finding of non-
ischaemic fibrosis in athletes describing its prevalence, distribution and clinical
importance.
Recent findings The strengths of CMR include high spatial resolution, unrestricted
imaging planes and lack of ionizing radiation. Regular physical exercise leads to
cardiac remodeling that in certain situations can be clinically challenging to differ-
entiate from various cardiomyopathies. Thorough morphological assessment by CMR
is fundamental to ensuring accurate diagnosis. Developments in tissue characteriza-
tion by late gadolinium enhancement and T1 mapping have the potential to be
powerful additional tools in this challenging clinical situation. Using late gadolinium
enhancement, it is also possible to detect non-ischaemic fibrosis in athletes who do
not have overt cardiomyopathy. The mechanisms of this fibrosis are unclear; however,
it does appear to be clinically important. We also review data on the prevalence of
non-ischaemic fibrosis in athletes.
Sports Imaging (M Papadakis, Section Editor)
* The Author(s) 2018
Summary CMR is a powerful tool to aid in the diagnosis of cardiomyopathy in athletes.
It may also have a future role in assessing fibrosis related to long-term participation
in sport.
Introduction
Long-term exercise leads to structural and functional
cardiac adaptation often termed ‘athlete’s heart’. Typical
features include left ventricular hypertrophy (LVH), left
ventricle (LV) and right ventricle (RV) cavity dilatation
and associated electrocardiographic (ECG) changes [1,
2]. Athlete’s heart facilitates an increase in stroke volume
and cardiac output as a physiological response to exer-
cise training and may potentially vary across different
types of exercise [3].
In clinical practice, it can be challenging to differen-
tiate the physiological changes of athlete’s heart from
cardiomyopathy, and in this review article, we will dis-
cuss both established and novel cardiovascular magnetic
resonance (CMR) techniques that may be helpful for
this purpose. Cardiomyopathy is one of the leading
causes of death in athletes and often once this diagnosis
is made precludes participation in competitive sport.
CMR, therefore, has a potentially vital role in improving
diagnosis [4].
Recent evidence suggests that prolonged participation
in certain sports may predispose certain individuals to
cardiac fibrosis, which may be associated with increased
risk of arrhythmias, particularly atrial fibrillation [5, 6].
In this systematic review, we discuss the role of CMR
in diagnosing cardiomyopathy in athletes and in partic-
ular review data on cardiac fibrosis.
CMR assessment of athlete’s heart
Echocardiography is the first-line investigation to assess cardiac morphology in
athletes given its low cost, widespread availability and lack of ionizing radia-
tion. CMR is increasingly used in clinical practice as it allows accurate visuali-
zation and quantification of the heart in any plane without limitation by
acoustic windows. Using CMR imaging, it is also possible to make an assess-
ment of myocardial tissue characteristics including fat and water content,
fibrosis and myocyte mass. By acquiring a stack of short-axis images with no
interslice gap with full ventricular coverage, it provides the opportunity to
inspect the entire LV myocardium for abnormalities, including focal hypertro-
phy or regional wall motion abnormalities. Unlike two-dimensional (2D)
techniques, cine CMR imaging does not rely on geometric assumptions or
calculations based on incomplete sampling of the cardiac volumes [7].
Gadolinium-based CMR contrast agents are exclusively extracellular and can
only passively enter damaged cells with a leaky cell membrane. This phenom-
enon is exploited in late gadolinium enhancement (LGE) CMR imaging. LGE
imaging involves administration of typically 0.1–0.2mmol/kg of a gadolinium-
based contrast agent. After a delay of 5–20min, the contrast agent is retained to
a greater extent than in areas of scar or fibrosis than in normalmyocardium. The
pattern of enhancement on LGE can aid in the diagnosis of cardiomyopathy.
For example, subendocardial or transmural LGE is typically seen in ischemic
cardiomyopathy, mid wall LGE in dilated and hypertrophic cardiomyopathies
and subepicardial LGE in myocarditis [8].
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T1mapping is a method for quantitative assessment of tissue characteristics.
The myocardial T1 time can be measured without contrast, native T1, or
following the administration of intravenous gadolinium-based contrast agent,
post-contrast T1. By combining both these measures, the myocardial extracel-
lular volume (ECV) fraction can be approximated, a value that has been
validated histologically in several cardiomyopathies [8].
Defining athlete’s heart
Morphology of the left ventricle in athlete’s heart has primarily been studied by
echocardiography with a clear pattern of LV dilatation and hypertrophy being
reported (although varying by sporting type) [1]. The improved reproducibility
of CMR has meant that it is possible to validate these findings, with a smaller
sample size and in longitudinal studies [9, 10, 11•]. This is exemplified by
Arbab-Zadeh et al.[11•] who demonstrated that 1 year of prolonged and
intensive endurance training leads to cardiac morphological adaptations in 12
previously sedentary young subjects similar to those observed in elite endur-
ance athletes.
Given the complex structure of the RVmorphological assessment by CMR is
more reproducible than echocardiography. Increases in RV mass, end diastolic
and stroke volumes relative to non-athletes have been described. The ratio of LV
to RV size was maintained, leading to the conclusion that athlete’s heart
syndrome involves balanced remodeling of both ventricles [10].
Differentiating physiology from pathology
Hypertrophic cardiomyopathy
Hypertrophic cardiomyopathy (HCM) is the leading cause of sudden cardiac
death in young athletes worldwide [12]. Traditional methods for differentiating
physiological left ventricular hypertrophy (athlete’s heart) fromHCMhave relied
on parameters derived from sedentary HCMpatients and healthy athletes. As the
leading cause of sudden cardiac death in younger populations, the discrimina-
tion of HCM from athlete’s heart has immediate clinical relevance [12].
In general, in subjects with good echocardiographic images, CMR provides
similar information on ventricular function and morphology but can provide
incremental diagnostic value in patients with poor acoustic windows or when
some LV regions are poorly visualized— such as the anterolateral wall, the LV
apex and the right ventricle [13, 14]. CMR also has a role in identification of
subtle markers of HCM including aneurysms, thrombi, myocardial crypts and
papillary muscle abnormalities [15].
Cine CMR can be used to differentiate athlete’s heart from pathological LVH
using multiple geometric measures. Petersen et al. reported that left ventricular
diastolic wall to volume ratio had the highest area under the curve (0.993)
providing a sensitivity of 80% and a specificity of 99% to distinguish athlete’s
heart from all forms of pathologic LVH [16].
Echocardiography tends to underestimate LA volumes andwhen assessed by
CMR atrial volumes are significantly larger in endurance athletes than controls
[17]. The presence of LA dilatation points more towards a diagnosis of athlete’s
heart than HCM [18].
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HCM is associated withmid wall fibrosis detected on LGE imaging predom-
inantly in areas of hypertrophy and is therefore useful in making the diagnosis.
LGE is only present in approximately two thirds of patients with HCM andmay
be even lower in athletes with HCM [19, 20]. In an athlete with unexplained LV
hypertrophy, the presence of typical scar may aid the diagnosis of HCM but its
absence cannot exclude it.
Using T1 mapping, it has been shown that in athletes, as fitness increases
there is an increase in myocyte mass, with a relatively constant extracellular
mass [21]. As shown by Swoboda et al. [22••], the negative correlation between
ECV and wall thickness in athletes and sedentary controls suggest that the
increase in LV mass in healthy myocardium is mediated by cellular hypertro-
phy. In HCM, there is a positive correlation between wall thickness suggesting
that hypertrophy is mediated by cellular disarray and extracellular matrix
expansion. Thus, CMR using T1mapping has a potential role in the exclusion of
HCM in athletes presenting with LV hypertrophy (Fig. 1).
Arrhythmogenic right ventricular cardiomyopathy
The diagnosis of arrhythmogenic right ventricular cardiomyopathy (ARVC) is
based on “Task Force” criteria (TFC) of clinical, histological and electrophysio-
logical and imaging parameters [23]. Imaging criteria require presence of both
qualitative findings (RV regional akinesia, dyskinesia, dyssynchronous contrac-
tion) and quantitative metrics (decreased ejection fraction or increased indexed
RV end-diastolic volume). Major CMR criteria have a sensitivity of 68 to 76%.
Minor criteria (RV ejection fraction 40–45%or indexed RV end-diastolic volume
100–110 mL/m2 for men and 90–100 mL/m2 for women) had a higher sensi-
tivity (79 to 89%), but a consequently lower specificity (85 to 97%) [23]. The
distal RV (from the moderator band to the apex) shows highly variable con-
traction patterns and regional wall motion abnormalities in the sub-tricuspid
region are more significant [24]. RV scarring detected on LGE is a common
Fig. 1. CMR using T1 mapping and ECV has a potential role in the exclusion of HCM in athletes presenting with LV hypertrophy.
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finding in ARVC; however, it is limited by the ability to acquire high-quality LGE
images of the RV free wall. This technique is therefore not routinely used [25].
Chronic RV abnormalities and acute dysfunction after endurance sporting
events have both been described. Heidbüchel et al. [26] proposed the term
“exercise-induced right ventricular cardiomyopathy” in reference to the dispro-
portionate rates of RV dysfunction in elite athletes presenting with serious
arrhythmias based on echocardiography, CMR and/or ventriculography. The
distinction between ARVC and the effects of exercise are not absolute, and
interestingly, exercisemay accelerate the development of ARVC in thosewho are
genetically predisposed [27]. On the other hand, a growing body of evidence
has suggested that athletes’ RV function is in fact superior to non-athletes as
reported by D’Andrea et al. [28]. Therefore, although athletes may have im-
paired RV function immediately after intense endurance exercise and in the
context of ventricular arrhythmias, healthy athletes, at rest, should have RV
functional measures that are at least as good as the nonathletic population. La
Gerche et al. [29•] tested the hypothesis that intense exercise may promote pro-
arrhythmic remodeling in some athletes. Exercise imaging was performed in 17
athletes with RV ventricular arrhythmias, of which eight (47%) had an im-
plantable cardiac defibrillator (ICD), 10 healthy endurance athletes and seven
non-athletes. Echocardiographic as well as CMR measures at rest and during
intense exercise combined with invasive measurements of pulmonary and
systemic artery pressures were obtained. Among athletes with normal cardiac
function at rest, exercise testing revealed RV contractile dysfunction among
athletes with RV arrhythmias. This is still a matter of ongoing debate that has
potentially been underappreciated. With recent advances in RV imaging CMR
may potentially elucidate some of these aspects.
Dilated cardiomyopathy
CMR is the reference technique for the quantification of ventricular volumes
and functional parameters, to measure wall thickness and ventricular mass in
patients with DCM [30]. Evidence suggests a significantly more heterogeneous
end-diastolic LV wall thickness in patients with DCM compared to normal
population. Also the physiological gradient in systolic wall thickening between
LV basal and apical segments disappears with DCM. RV mass has also been
shown to be preserved in DCM patients as compared to normal subjects,
whereas LV mass is significantly greater with evidence of larger trabeculae as
compared to normal subjects [30, 31], while in advanced cases, LV dysfunction
may be associated with diffuse myocardial wall thinning (diastolic wall thick-
ness G 5.5 mm) [30, 31]. LGE has been described as being present in patients
with DCM in 12–35% of the cases, the most common pattern being charac-
terized by a midwall linear distribution which might represent the intramural
layer of septal fibrosis which has been observed in pathologic samples [30, 32].
In themost extreme athletic training, cardiac remodeling can be profound. It
was shown by means of echocardiography on 286 Tour de France cyclists that
more than half of the athletes had LV diastolic dimensions exceeding 60 mm
and 11.7% had a left ventricular ejection fraction (LVEF) ≤ 52%. This may pose
significant difficulty in differentiating athlete’s heart from DCM [33].
If resting measures do not differentiate the athlete from the patients, poten-
tially systolic dysfunction during exercise might be an important aspect.
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Abernethy et al. [34] demonstrated good augmentation of systolic function in
professional footballers with low normal LVEF. Some studies in heart failure
populations have observed no exercise induced increment in LVEF using echo-
cardiography whereas others reported some degree of augmentation [32].
Claessen et al. [35] have proposed that contractile reserve can be assessed by
exercise CMR and to discriminate physiological and pathological LV remodel-
ling impairment of LV ejection fraction.
Both native T1 and ECV have been shown to be elevated in patients with
DCM, even in those without midwall fibrosis [36, 37]. A study comparing early
DCM (N = 16) and exercisers with low normal LVEF (N = 21) showed that
exercisers had normal native T1 and ECV whereas both were elevated in those
with DCM and this difference could be used to discriminate the two groups [38].
Left ventricular non-compaction cardiomyopathy
Non-compaction cardiomyopathy occurs due to an autosomally dominant
inherited trait in which the middle and apical segments exhibit a thin compact
wall with regional dilatation, dysfunction and significant hyper-trabeculation.
There are different definitions including an end-diastolic ratio of non-
compacted to compacted LV myocardium of greater than or equal to 2.3. Also,
LV wall motion abnormalities, global dysfunction or coronary intraventricular
thrombi are often present in the disorder [39].
However recently, an unexpectedly large prevalence of LVNCC has been
reported in athletes, raising the question of the appropriateness of current
diagnostic criteria [40, 41]. In a large athlete population comprising 2501
consecutive athletes who underwent a cardiac evaluation including physical
examination, ECG, exercise test and echocardiography and additionally CMR, a
marked LV trabecular pattern was seen in 1.4%. Only a small subset of these
athletes (0.1%) showed familial, clinical and morphologic changes supporting
the diagnosis of LVNCC. It is important to note that the majority of athletes
with increased trabeculations were not associated with LV dysfunction and/or
positive family history, likely representing a morphologic LV variant, of limited
clinical significance [42].
CMR coronary imaging
Anomalous coronary arteries are relatively common cause of death during sport
particularly when the coronaries have a malignant interarterial course [4]. The
course of the coronary arteries can be depicted by CMR either with or without
administration of contrast [43]. CMR coronary imaging does not expose the
athlete to ionizing radiation and is therefore an ideal test for young athletes.
Coronary magnetic resonance angiography has been used in a study with 335
individuals (including 207 athletes) with a malignant variant of the right
coronary artery identified in four subjects [44].
Myocardial fibrosis in athletes
Several studies have reported myocardial fibrosis (MF) detected by LGE CMR
although the prevalence and pattern have varied (Table 1). However, the causes
and mechanisms of MF are unclear. Tahir et al. [47••] comparing 83
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asymptomatic triathletes undergoing 9 10 training h per week and 36 sedentary
controls using LGE and extracellular volume (ECV) CMR demonstrated focal
nonischemic MF in 9 of 54 (17%) male triathletes but in none of the female
triathletes. Fibrosis was associated with exercise-induced hypertension and the
race distances. Merghani et al. [45•] assessed 152 master athletes 54.4 ±
8.5 years of age and 92 matched controls with low Framingham 10-year
coronary artery disease risk scores in the aim of identifying the prevalence of
subclinical coronary artery disease. Most athletes and controls had a normal
coronary artery score (CAC) score; however, male athletes had a higher preva-
lence of atherosclerotic plaques of any luminal irregularity (44.3 versus 22.2%)
compared with sedentary males. Of note, male athletes demonstrated pre-
dominantly calcific plaques (72.7%), whereas sedentary males showed pre-
dominantly mixed morphology plaques (61.5%) and the number of years of
training was the only independent variable associated with increased risk of
CAC. Interestingly, in regards to the CMR findings, 14%male athletes but none
of the controls revealed LGE, half of whom had a pattern consistent with
previous myocardial infarction. Earlier, Wilson et al. [49] having examined 12
lifelong veteran male endurance athletes, 20 age-matched veteran controls and
17 younger male endurance athletes without significant comorbidities, dem-
onstrated that in six (50%) of the veteran athletes, LGE of CMR indicated the
presence of myocardial fibrosis and in one case, the pattern was consistent with
previous episode of acute myocarditis.
Also, the amount and intensity of exercise training, as well as the lifelong
exercise exposure should be taken into account to test the hypothesis that MF
prevalence differs between athletes and the general population.
Patterns of myocardial fibrosis
There is a growing body of literature showing that the phenotype of MF in
athletes demonstrates large variance in patterns, location and quantifica-
tion. More specifically, MF in athletes has been noticed to be divided into
two main categories: non-ischemic and ischemic scar. These phenotypes
seem to differ from that in the general population, which may be relevant
for the underlying mechanisms and clinical prognosis of MF in apparently
healthy athletes. As noted by Merghani et al. [45•], 14% of veteran male
athletes but none of the controls revealed LGE, half of whom had a pattern
consistent with previous myocardial infarction. On the other hand, Tahir
et al. [47••] demonstrated in 83 asymptomatic triathletes using LGE and
ECV CMR focal non-ischemic MF in 9 of 54 (17%) males but in none of the
female triathletes. In lifelong veteran endurance athletes, MF has been
reported near the septal insertion points of the RV free wall in 37% of the
athletes with just one subject exhibiting sub-epicardial lateral wall fibrosis
[51]. This phenotype seems to differ from that in the general population,
which may be relevant for the underlying mechanisms and clinical prog-
nosis of MF in apparently healthy athletes.
A dose-response relationship?
It is very well established that regular exercise improves cardiovascular risk
profile, reduces the risk of myocardial infarction by 50% and is related with a
variety of other beneficial effects. Most of these benefits are attributable to
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moderate exercise. Intense exercise, however, may infrequently trigger arrhyth-
mogenic sudden cardiac death in asymptomatic cardiac disease. Moreover,
long-standing vigorous exercise may be associated with adverse electrical and
structural remodelling in otherwise normal hearts which may be a dose-
response phenomenon [52].
In parallel, evidence from case reports/series suggests that athletes diagnosed
as having MF demonstrate high doses of exercise for many years. These studies
and case reports suggest a dose-response relationship between lifetime exercise
exposure and MF development [53]. Larger studies, such as by Tahir et al.
[47••], demonstrated focal non-ischemic MF in 17% males. A cycling race
distance of 9 1880 km completed during competition had the highest accuracy
to predict LGE, with an area under the curve value of 0.876, resulting in high
sensitivity (89%) and specificity (79%). Also, the swimming race distance was
noted to be independent predictors of LGE presence. La Gerche et al. [54]
studied 40 athletes at baseline, immediately following an endurance race (3–
11 h duration) and 1-week post-race. LGE localized to the interventricular
septum was identified in 5 of 39 athletes who had greater cumulative exercise
exposure. Furthermore, in 108 apparently healthy male marathon runners with
≥ 5 marathon competitions during the previous 3 years, the presence of LGE
and of coronary artery calcification (CAC) in relation to cardiovascular risk
factors was evaluated. It was noted that CAC percentile values and number of
marathons independently predicted the presence of LGE [55].
In contrast, another report provided evidence of potential myocardial
injury and ventricular dysfunction after prolonged exercise using CMR im-
aging before and after amateur marathon races in 28 healthy males. Al-
though marathon running led to a transient increase of cardiac biomarkers,
no detectable myocardial necrosis was observed as evidenced by LGE [56]. It
is important to note that existing data is conflicting and the majority lacks
direct verification of functional myocardial alterations by CMR especially in
large number of athletes. Larger, well-designed studies, based on well-
defined criteria of athletes’ populations are needed in order to reach safe
conclusions.
Clinical implications
The presence of MF is an important risk factor for adverse cardiac outcomes in
clinical populations. However, the prognostic value of MF has not been exten-
sively studied in athletic population [51]. The impact of lifelong exercise
training is still a matter of ongoing debate. Although there are data supporting a
U-shaped association between exercise volume and cardiovascular risk, most
available evidence suggests a curvilinear relationship, with greater health ben-
efits at larger exercise doses [51, 57]. Several studies have identified the presence
of LGE in the heart of extensively trained veteran athletes. LaGerche et al. [47••]
have shownmyocardial fibrosis by CMR and a reduction in RV systolic function
in athletes with long-term exercise, suggesting that the heart has a limited
capacity to tolerate the overload exercise. Some authors have also a new entity,
the so called “Phidippides cardiomyopathy”; long-term strenuous exercise can
induce cardiac dilation and also activates resident macrophages, pericytes and
fibroblasts, resulting in the deposition of collagen and fibrosis. It may be
possible that the RV is more susceptible to fatigue than the left ventricle after
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prolonged exercise although more studies are required to identify a probable
effect of exercise “dose” and their implication in the development of heart
failure [58].
In addition, nonischemic LV scar, which is characteristically localized at
the mid-myocardial or subepicardial layers of the LV wall, can be found as
mentioned above, in a broad spectrum of heart muscle diseases at risk of
sudden cardiac death (SCD), including myocarditis, sarcoidosis, DCM,
HCM and ARVC. Whether this isolated, segmental LV myocardial lesion
may act as a substrate of life-threatening arrhythmias and SCD in the
athlete remains to be elucidated. Also, the presence of LGE at the junction
of the RV with the ventricular septum has been consistently reported in a
sizeable proportion of endurance athletes and related to the duration and
intensity of sports activity but this pattern is traditionally deemed a non-
clinically relevant; however, follow-up studies evaluating its arrhythmic
risk are lacking [53]. Zorzi et al. [59] evaluated 35 athletes with ventricular
arrhythmias by CMR and compared with 40 healthy control athletes. A
stria LGE pattern with subepicardial/midmyocardial distribution, mostly
involving the lateral LV wall, was found in 27 (77%) versus 0 in controls,
whereas a spotty pattern of LGE localized at the junction of the right
ventricle to the septum was, respectively, observed in 11 (31%) versus 10
(25%) though this did not reach statistical significance.
It is important to emphasize that the prognostic significance of nonspecific
MF patterns seen in athletes is yet to be clarified as there is no significant
evidence currently, that athletes with this pattern should be restricted from
exercise.
Conclusions
Multimodality cardiac imaging has been used in all of its forms to study the
intrigues of the athlete’s heart syndrome. A description of the changes in cardiac
morphology and function has permitted this syndrome to be differentiated
from serious cardiac pathology, which may mimic it in many cases. Cardiac
imaging has not successfully and conclusively answered this question, although
recent advances in CMRwho great promise. MF has been reported in endurance
athletes and the pattern of LGE is heterogeneous, which may represent different
causes and prognostic significance. Larger, well-designed studies, based onwell-
defined criteria of athletes’ populations are needed in order to reach safe
conclusions.
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